MindMed Reveals Favorable Results From Phase 1 Trial Of Drug Candidate For Opioid Withdrawal Treatment

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced today the topline results from the phase 1 clinical trial for its opioid withdrawal treatment drug candidate. The drug is said to have shown favorable safety and tolerability among the trial’s subjects.

“As there is a major unmet need to address the ongoing and ever-growing opioid crisis, we are very pleased with the results from our Phase 1 trial, which underscore the potential clinical utility of MM-110 to safely mitigate symptoms of opioid withdrawal,” said Chief Medical Officer Dr. Daniel Karlin.

The phase 1 trial was designed to assess the safety, tolerability, pharmacokinetics, and neurocognitive effects of MM-110 in 108 healthy subjects. The results showed that the drug administration was well-tolerated up to 500mg per day in the single ascending dose and 60 mg per day for seven days in the multiple-ascending dose.

No serious adverse effects were also observed in the trial.

According to the biotech firm, MM-110 is an α3β4 nicotinic cholinergic receptor antagonist and non-hallucinogenic proprietary congener of ibogaine.

The results have been guiding the firm’s upcoming phase 2a trial.

Mind Medicine Inc. last traded at $0.94 on the NEO.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Barrick Mining’s “Company Defining [Gold] Discovery”

America Uses More Copper Than It Makes | Simon Quick – Canadian Copper

Gold Bulls Run Faster Than New Mines?! | Thomas Mumford – Scottie Resources

Recommended

ESGold Secures $9 Million In Non-Dilutive Funding From Ocean Partners

Altamira Gold Encounters Porphyritic Intrusive Rocks In Initial Scout Drilling At Regional Targets

Related News

MindMed Signs Collaboration Agreement with Swiss Psychedelic Research Lab

Mind Medicine Inc (NEO: MMED) has entered into an exclusive collaboration with Professor Dr. Liechti’s...

Wednesday, April 1, 2020, 11:55:12 PM

MindMed Adds MDMA To R&D Pipeline

Mind Medicine, also known as MindMed (NEO: MMED) this morning announced that it is branching...

Wednesday, May 27, 2020, 09:00:04 AM

Mind Medicine Sees Final Co-Founder Leave The Company

Mind Medicine (NEO: MMED) appears to now be fully under new management. On Friday evening,...

Sunday, January 9, 2022, 03:07:00 PM

Mind Medicine Sees FDA Place Clinical Hold On Phase 2b Study

Mind Medicine (NEO: MMED) this morning indicated that things are not going quite to plan...

Tuesday, December 21, 2021, 08:22:51 AM

MindMed Declares US$17.0 Million Net Loss, US$105.7 Million Cash Balance For Q2 2022

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced on Thursday its financial...

Friday, August 12, 2022, 08:20:03 AM